
Girls' basketball notebook: In memory of loved ones, Lincoln-Sudbury teams up in Hoops 4 Hope
They also created a 'Hope Wall' outside the gym, where people could sign and leave notes and names of family members and friends who have battled all types of cancer.
Get Starting Point
A guide through the most important stories of the morning, delivered Monday, Wednesday, and Friday.
Enter Email
Sign Up
While it was certainly an emotional evening, it wasn't necessarily a somber one. The senior Schwartz and the two juniors know their relatives would have wanted them to continue to play with joy, even in their absence.
Advertisement
'It wasn't about despair and sadness,' Lincoln-Sudbury coach
Howie Landau
said. 'It was about happiness, and the emotion of bringing the community together.'
When Poland, Wallerstein, and members of the L-S volleyball team conducted an event for breast cancer awareness last fall, they decided they should try to do something similar for basketball. With their shared experiences as a driving force, they worked diligently to launch the plan.
'It's definitely affected us as a team and a program, so I thought this would be a really special moment,' Poland said.
Landau was completely for the idea, and together they started to spread the word. He's grateful to the Lincoln-Sudbury community and administration, plus coach
Cheryl Seavey
and the Bridgewater-Raynham program, for helping to turn it into a reality.
L-S athletic director
Dan Lee
said he's always impressed at the initiative and social awareness of the school's student-athletes. He said the planning of this night was student-driven and is a wonderful example of how student-athletes can use the platform of sport to bring initiatives to the broader community.
Advertisement
'What makes the Lincoln-Sudbury community special is its unwavering spirit of unity and compassion, exemplified through events like Hoops 4 Hope,' Lee said. 'These initiatives reflect the heart of our community — where people come together not just to raise awareness, but to actively support and honor causes that make a lasting impact.'
Schwartz, who has raised money through the cancer research organization 'A Shot For Life' with her brother,
Ben
, is grateful to have multiple communities that provide hope. She continues to think of her father every step of the way as she gives back.
'Playing basketball kind of became a way for us to keep his memory alive,' Schwartz said.
Schwartz, averaging 12.6 points, 6.4 rebounds, and 4 assists per game, said her father used to love Eminem's song 'Lose Yourself.' He played it before he got chemo and had surgery as a way to get himself in the right frame of mind, and she still thinks of it often before she competes.
Lincoln-Sudbury's Evie Schwartz, (32), pictured dishing a pass against Bridgewater-Raynham, lost her father, Ken, to brain cancer in 2021. 'Playing basketball kind of became a way for us to keep his memory alive,' she said.
Barry Chin/Globe Staff
Wallerstein, contributing 9.5 points, 8.1 rebounds, and 1.7 blocks a night, wears No. 21 in honor of her sister. She designed the T-shirts for the event and made sure to set the tone Friday.
'When my sister was going through everything, she was never sad,' Wallerstein said. 'She was always upbeat. I want to make sure everyone on the team is smiling and having a fun time, even though it was an emotional night.'
Landau said Wallerstein's mother,
Elin
, told him that Alice's 3-year-old sister,
Iris
, got really excited in the crowd when she heard Lea's name.
Poland, averaging 12.7 points, 8.1 rebounds, and 3.6 assists, has seen the way her grandfather's death affected her mother. She views basketball as an outlet to 'let everything out' and used the event as a way to honor his legacy.
Advertisement
All three mothers and all three players have bonded through shared grief. When Schwartz, Poland, and Wallerstein each made the team, their separate but overlapping experiences were critical in bringing them together.
As devastating as each loss has been, the heartbreak they've endured has helped them grasp the fragility of life and the value of family.
'We're all close even without it, but it's brought us closer,' Wallerstein said.
Lincoln-Sudbury's Sarah Poland, (22), drawing a host of Bridgewater-Raynham defenders on a drive, views basketball as an outlet to 'let everything out,' and used the Hoops 4 Hope event as a way to honor her grandfather's legacy.
Barry Chin/Globe Staff
Alice Wallerstein (21), driving through a B-R double team, said her late sister, Lea, was never sad. She "was always upbeat. I want to make sure everyone on the team is smiling and having a fun time, even though it was an emotional night.'
Barry Chin/Globe Staff
Courtside chatter
▪ An impact player on varsity since she first stepped on the court at Notre Dame (Hingham) as a seventh grader,
Ava Orlando
joined the notable 2,000-point club with her 31-point, 10-assist, 6-steal performance in Friday's 79-44 nonleague win over Longmeadow. Only 81 other players in state have reached the lofty total.
'It was great to see my teammates so happy for me,' said Orlando, who surpassed the milestone with a second-quarter 3-pointer in transition. 'Hopefully we can continue to make memories with our tournament run.'
Orlando can think on a dime mid-dribble, which is how she generates scoring.
'I let the opponent guess what I'm doing next,' Orlando said. 'Just with my overall IQ, knowing when to go and not to go, and moving the ball around me plays into it.'
On Tuesday, NDA will honor Orlando before the Cougars take on Fontbonne at 6:30 p.m.
▪ With five key players sidelined, Blue Hills is making up for its losses with a 'next-person up' approach. Freshman center
Sarah Michel
, for one, is playing like a veteran.
The 5-foot-10-inch underclassman is leading the Warriors (12-0) with 16.9 points and 11 rebounds per game.
Advertisement
'She kind of does it all for us right now,' coach
Nicole Flynn
said.
In a Mayflower Athletic Conference win over Bristol-Plymouth last Tuesday, Michel netted a career-high 27 points. In the following two games, she combined for another 32.
'She definitely scores really well down low, but there are other times where she'll rebound and go on a fastbreak,' said Flynn. 'She has the ability to go coast to coast, and she definitely is someone who the bigger the game is, the better she performs.'
▪ With four returning starters, plus the first reserve off the bench, Bourne (12-1) sits atop the South Coast Conference.
Coach
Steve Wenzel
has a number of options, with senior captains
Paige Meda
(16.5 points per game) and
McKinley Wenzel
(12.5 ppg), his daughter, spearheading the operation.
'We play a multitude of offenses depending on what we're seeing,' Wenzel said. 'We can spread, high-screen roll, or we can run sets, the old-school two in the posts and three guards dump it in. I have some high-level IQ forwards, so our inside-out game is pretty solid.'
Junior bigs
Raeghan Blake
and
Nola Timo
average 8 rebounds per game, and junior guard
Aubrey France
averages 6 steals, leading the league.
'From tryouts to launching the season, we've really been ahead of schedule,' Wenzel said. 'That's really been the key.'
Games to watch
Tuesday, No. 3 Woburn at Reading, 7 p.m.
— A matchup of the top two teams in the Middlesex League's Liberty Division.
Friday, No. 11 Braintree at Walpole, 6 p.m.
— The Timberwolves have had their moments, but the hosts will need to be at their best in this Bay State-Herget showdown.
Advertisement
Friday, No. 15 Pembroke at No. 16 North Quincy
— In a stacked Patriot-Fisher division, two of the top three teams go head-to-head in this top-20 matchup.
Friday, Framingham at No. 14 Natick, 6:30 p.m.
— The Flyers have stood out with wins against Lincoln-Sudbury and Natick early in the season, making this an intriguing matchup.
Saturday, No. 8 Dartmouth at No. 4 St. Mary's, 7 p.m.
— This nonleague contest features two of the state's most prolific squads.
Correspondent Graham Dietz contributed to this story.
Trevor Hass can be reached at
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
3 hours ago
- Business Wire
Corpay Cross-Border Named the Official FX Partner of New Zealand Football
TORONTO--(BUSINESS WIRE)--Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, is pleased to announce that Corpay's Cross-Border business has entered into an agreement with New Zealand Football to become their Official Foreign Exchange (FX) Partner. Through this partnership, New Zealand Football will be able to utilise Corpay Cross Border's innovative solutions to help mitigate foreign exchange exposure from their day-to-day business needs. Additionally, Corpay Cross-Border's award-winning platform will enable them to manage their global payments from a single point of access. "Corpay Cross-Border would like to congratulate New Zealand Football and the All Whites for qualifying to compete at the 2026 FIFA World Cup," said Brad Loder, Chief Marketing Officer, Corpay Cross-Border Solutions. 'With our strong focus on growing the Corpay brand, as well as our corporate payments and currency risk management business in New Zealand, we look forward to working with New Zealand Football as their Official FX Partner in their pursuit of the World Cup and for many years to come.' 'As we grow and mature as an organisation, we need to continue to evaluate the way we do business internationally, and partnerships such as this, with a major financial organisation, illustrate how we are now thinking on a global scale,' said Andrew Pragnell, CEO at New Zealand Football. 'It is great to partner with Corpay at a really exciting time for football, where the game is only going from strength to strength at all levels in Aotearoa New Zealand.' About Corpay Corpay, Inc. (NYSE: CPAY) is a global S&P500 corporate payments company that helps businesses and consumers pay expenses in a simple, controlled manner. Corpay's suite of modern payment solutions help its customers better manage vehicle-related expenses (such as fueling and parking), travel expenses (e.g. hotel bookings) and payables (e.g. paying vendors). This results in our customers saving time and ultimately spending less. Corpay Cross-Border refers to a group of legal entities owned and operated by Corpay, Inc. Corpay – Payments made easy. To learn more visit *'Corpay' in this document primarily refers to the Cross-Border Division of Corpay, Inc. a full listing of the companies that are part of Corpay Cross-Border is available here:
Yahoo
6 hours ago
- Yahoo
DexCom Expands Access and Innovation While Balancing Headwinds
DexCom, Inc. DXCM reported second-quarter 2025 results that highlighted robust top-line growth, continued progress in expanding access and meaningful product innovation. Revenues grew 15% year over year to $1.16 billion, with broad-based contributions from both the U.S. and international markets. Management raised full-year revenue guidance to $4.6-$4.625 billion, reflecting confidence in ongoing momentum, particularly in the type 2 non-insulin segment. At the same time, the company faces competitive pressures, regulatory uncertainties and operational hurdles, all of which affect the near-term risk-reward balance. With a leadership transition ahead, DexCom remains positioned for long-term expansion. DexCom share have gained 4% so far this year against the industry's decline of 7%. The S&P 500 Index increased 8.8% in that period. Image Source: Zacks Investment Research Short-Term Growth Drivers U.S. Expansion in Type 2 Non-Insulin Coverage: The most immediate growth catalyst is the rapid expansion of coverage for type 2 non-insulin patients. As of the second quarter, DexCom secured reimbursement with all three major U.S. PBMs, providing access to nearly 6 million covered lives. This development is already translating into strong new patient starts, reinforcing management's confidence in raising guidance. Importantly, clinicians are increasingly integrating CGM into earlier stages of care, accelerating adoption within primary care channels. Stelo Momentum and Consumer Adoption: DexCom's over-the-counter biosensor, Stelo, continues to gain traction. The app surpassed 400,000 downloads this summer, with rising adoption among wellness users and prediabetic populations. Partnerships with platforms like Oura and Amazon are broadening distribution and enhancing digital integration. While Stelo currently represents just 2-3% of revenues, it demonstrates the potential for DexCom to diversify beyond traditional diabetes management into broader metabolic health. 15-Day G7 Sensor Launch: FDA clearance for the 15-day G7 sensor marks another short-term catalyst. A potential launch in the rest of 2025 should support utilization and potentially improve gross margin dynamics as reimbursement negotiations shift toward monthly coverage models. This longer-wear sensor enhances convenience and strengthens DexCom's competitive positioning. Operational Improvements in Supply Chain: After supply constraints earlier in the year, DexCom restored inventory levels by executing record production months and leveraging expedited shipping. The company also rolled out a nationwide warranty program for pharmacy customers, bolstering service reliability. These operational stabilizations should mitigate near-term disruption risk and support smoother growth in the second half. Long-Term Growth Drivers Expanding International Coverage: International revenues grew 16% in the second quarter, led by DexCom ONE+ adoption. Coverage wins in regions such as Ontario, Canada, and France underscore growing global recognition of CGM's clinical and economic value. In markets like Japan and Germany, low penetration of basal insulin users presents a substantial long-term opportunity. Management expects further international expansion across both established and emerging markets to remain a durable growth pillar. Next-Generation G8 Platform and Multi-Analyte Sensing: Looking further, DexCom's G8 sensor platform represents the next major leap in CGM technology. Designed to be 50% smaller, with multi-analyte sensing capabilities, G8 could expand the addressable market by addressing broader metabolic monitoring needs, including ketone detection. While timelines depend on clinical and regulatory milestones, G8 is expected to reinforce DexCom's innovation leadership and strengthen competitive differentiation. Broader Clinical Applications: DexCom is also advancing evidence generation to expand CGM usage beyond diabetes. Recent clinical trials demonstrated benefits for gestational diabetes and type 2 non-insulin users, while early studies suggested positive outcomes in chronic kidney disease. As real-world evidence accumulates, these findings could pave the way for new reimbursement approvals and expanded adoption across metabolic health conditions. Software and AI Integration: DexCom continues to operate with a 'consumer technology mindset,' rolling out 17 app updates in the first half of 2025 alone. Innovations such as AI-enabled smart food logging, seamless integration with wearables like Oura, and enhanced data visualization enrich user experience and increase retention. These digital enhancements help transform CGM from a monitoring device into a comprehensive health platform, reinforcing customer loyalty and utilization. DXCM's Sales & EPS Estimates Image Source: Zacks Investment Research Challenges Margin Pressures and Inventory Costs: Despite revenue growth, gross margin contracted to 60.1% from 63.5% a year ago, largely due to higher logistics costs and expedited shipping. While management expects sequential improvement as supply-chain normalization continues, sustained investment in distribution and warranty programs may weigh on profitability in the near term. Competitive and Regulatory Uncertainty: DexCom faces intensifying competition, particularly from Abbott ABT, which is strengthening its integration with insulin pumps and advancing new sensor platforms. In addition, the CMS proposal for competitive bidding in CGM and pumps, while still preliminary, poses a medium-term risk. Medicare represents roughly 15% of DexCom's business, and any pricing compression could affect margins starting as early as 2027. Leadership Transition: CEO Kevin Sayer will step down in early 2026, handing leadership to current president Jake Leach. While Leach has been with DexCom since its inception and is well regarded, transitions of this magnitude always carry execution risk. Ensuring continuity of strategic focus, particularly across innovation and global expansion, will be critical. Conservative Guidance and Execution Risk: Although management raised revenue guidance, it remains cautious about the back half, citing the need to meet commitments despite outperformance in the first half. This conservatism reflects execution challenges around scaling new coverage wins, driving sustained utilization and balancing global expansion with profitability. Competition Update Abbott continues to assert dominant momentum, driven largely by its FreeStyle Libre portfolio. The company reported a strong 18.3 % increase in continuous glucose monitor sales in first-quarter 2025, boosting medical device revenues by 9.9 % — beating EPS forecasts for the 21st consecutive quarter. Underpinning its success, Abbott projects Libre franchise annual sales could reach $10 billion by 2028, fueling investor optimism around expanded CGM adoption. Roche RHHBY has maintained steady growth across its Diagnostics arm, achieving 6% sales growth in first quarter of 2025 on a constant-exchange-rate basis. Roche is advancing CGM technology, showcasing an AI-enabled SmartGuide system that predicts glucose trends and hypoglycemia up to two hours ahead. These innovations reinforce Roche's potential to integrate predictive analytics into diabetes care and expand its CGM footprint. Medtronic MDT is gaining traction with its Smart MDI and MiniMed 780G systems. Real-world data show that users of Medtronic's Smart MDI system achieved Time-in-Range averages of 67% to 71% when acting on insulin-alert prompts. Separately, use of the Medtronic's MiniMed 780G with SmartGuard improved HbA1C by 0.6% and increased Time-in-Range by nearly 10% versus manual insulin delivery. DexCom, Inc. Price DexCom, Inc. price | DexCom, Inc. Quote Conclusion DexCom delivered another quarter of strong double-digit growth, underpinned by expanded access, international traction and product innovation. The company's leadership in CGM technology, coupled with growing evidence supporting broader use cases, provides a compelling long-term narrative. However, margin pressures, regulatory uncertainty, competitive threats and the looming CEO transition temper near-term enthusiasm. At current levels, the stock reflects both opportunity and risk in equal measure. Investors should continue to hold the stock and wait for greater clarity on execution in type 2 non-insulin adoption, international scale-up, and margin recovery before revisiting a more bullish outlook. DexCom currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Roche Holding AG (RHHBY) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data


Business Wire
13 hours ago
- Business Wire
Bonerge Unveils StanYouth® CR3: A Revolutionary Anti-Aging Complex Merging TCM Wisdom and Cellular Science
NEW YORK--(BUSINESS WIRE)--Bonerge has unveiled its revolutionary anti-aging Product, StanYouth® CR3, a patented formula that bridges Traditional Chinese Medicine (TCM) philosophy with cutting-edge cellular science. Inspired by TCM's "Senolytic-Repair-Chi" theory, this synergistic complex targets aging at the cellular level, offering a multi-dimensional solution to combat senescence. Rooted in the TCM principle of "treating disease before it arises," StanYouth® CR3 operates through a three-stage mechanism mirroring "Senolytic-Repair-Chi." Its core ingredients—Fisetin (FIS), Urolithin A (UA), and L-Ergothioneine (EGT)—work in harmony to address aging at its source. Fisetin: The Senolytic Purifier As a natural flavonoid with superior cell membrane penetration, Fisetin selectively eliminates senescent cells—dysfunctional cells that linger and secrete pro-inflammatory senescence-associated secretory phenotypes (SASP), accelerating tissue aging. It not only clears existing senescent cells but also reduces new ones, cutting inflammatory factor production at the source to purify the cellular environment [1,2]. Urolithin A: The Homeostasis Restorer Cellular aging thrives on disrupted metabolic and circadian rhythms, which worsen inflammation and weaken clock gene function. Urolithin A repairs this balance by regulating core clock genes (e.g., CLOCK, PER2) critical for gut metabolism and boosting the expression amplitude of BMAL1 in senescent cells, restoring their circadian rhythms and metabolic homeostasis [3,4]. L-Ergothioneine: The Defense Enhancer Environmental stress and metabolism generate reactive oxygen/nitrogen species (ROS/RNS) that damage DNA and deplete vitality. L-Ergothioneine, via its unique OCTN-1 transporter, accumulates in high-oxidative-stress areas like mitochondria and nuclei, neutralizing free radicals in real time. It also upregulates endogenous antioxidant enzymes, strengthening cellular resilience and nourishing vital energy ("Chi")[5,6]. Synergistic Power: A Closed-Loop Mechanism Together, they form a "Senolytic-Repair-Chi" cycle. Fisetin clears senescent burdens, creating a healthy foundation; Urolithin A restores rhythms and metabolism; L-Ergothioneine fortifies defenses, preventing further damage—each amplifying the others' effects. Cellular Experiments Validate Superiority Tests on human dermal fibroblasts revealed striking results: StanYouth® CR3 cleared up to 80% of senescent cells, doubling Fisetin's solo performance. It suppressed senescence markers p16 and p21 to near-normal levels, outperforming single ingredients. Critically, it reduced pro-inflammatory IL-6, IL-8, and fibrosis-driving IL-11 to baseline, blocking the "senescence-inflammation-fibrosis" cycle. It also inhibited UVB-induced ROS and boosted cell migration —key for repair—far better than individual components. Clinical Trial Confirms Efficacy A 56-day human trial showed StanYouth® CR3 outperformed standalone L-Ergothioneine: skin firmness (F4) rose 16.3%, under-eye wrinkles fell 11.28%, brightness (L*) increased 1.4%, and fairness (ITA) improved 6.10%, skin barrier repair (TEWL reduction) reached 18.18%. "StanYouth® CR3 is more than an anti-aging formula— it's a bridge between ancient TCM wisdom and modern cellular science," noted a Bonerge product manager. By translating the holistic "Senolytic-Repair-Chi" principle into a precise, synergistic cellular strategy, it delivers proven efficacy from laboratory to real-world application. As Bonerge continues to explore its potential beyond skin health, StanYouth® CR3 marks a new era in evidence-based anti-aging, where tradition and innovation converge to redefine vitality. References [1] Kento Takaya, et al. Biogerontology. 2024 Feb;25(1):161-175. [2] Li Zhang, Xiang Tong, et al. Front Pharmacol. 2020 Dec 14:11:553690. [3] Yao Du, Xinyue Chen et al. Nutrients 2024, 16, 2263. [4] Rassul Kuatov, Jiro Takano et 2024 Dec 25;17(1):20. [5] Hui-Min Liu, Wei Tang, et al. Molecules. 2023 Feb 8;28(4):1648. [6] Yasaaswini Apparoo, Chia Wei Phan, et al. Exp Gerontol. 2022 Dec:170:111982.